Linda Palczuk - 12 Feb 2026 Form 4 Insider Report for AVADEL PHARMACEUTICALS PLC (AVDL)

Reporting relationship: Director
Issuer ticker: AVDL
Reported as of: 12 Feb 2026
Net transaction value: -$1,657,005
SEC form: 4
Accepted by SEC: 12 Feb 2026, 17:35:08 UTC
Prior SEC filing: 15 Sep 2025
Source filing: View source filing
Reporting owner signature: /s/ Robert E. Puopolo, as Attorney-in-Fact

Key filing fact

Linda Palczuk filed Form 4 for AVADEL PHARMACEUTICALS PLC (AVDL) on 12 Feb 2026.

Key facts

This page summarizes Linda Palczuk's Form 4 filing for AVADEL PHARMACEUTICALS PLC (AVDL).
9 reported transactions and 8 derivative rows are listed below.
Accepted by SEC: 12 Feb 2026, 17:35.

Change

Previous filing in this sequence was filed on 15 Sep 2025.
Current net transaction value: -$1,657,005.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001717580 Primary reporting owner

Palczuk Linda

Relationship: Director
Address: C/O AVADEL PHARMACEUTICALS PLC, 10 EARLSFORT TERRACE, DUBLIN 2, IRELAND
Signature: /s/ Robert E. Puopolo, as Attorney-in-Fact
Signature date: 12 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AVDL transaction

Ordinary Shares

Disposed to Issuer

Transaction value: $1,657,005
Shares: -78,905
Change %: -100%
Price: $21.00
Shares after: 0
Date: 12 Feb 2026
Ownership: Direct
Footnotes: F1, F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AVDL transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -60,000
Change %: -100%
Price
Shares after: 0
Date: 12 Feb 2026
Ownership: By Trust
Underlying class: Ordinary Shares
Underlying amount: 60,000
Exercise price: $2.03
Footnotes: F4, F5

AVDL transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -42,000
Change %: -100%
Price
Shares after: 0
Date: 12 Feb 2026
Ownership: By Trust
Underlying class: Ordinary Shares
Underlying amount: 42,000
Exercise price: $8.48
Footnotes: F4, F5

AVDL transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -42,000
Change %: -100%
Price
Shares after: 0
Date: 12 Feb 2026
Ownership: By Trust
Underlying class: Ordinary Shares
Underlying amount: 42,000
Exercise price: $8.07
Footnotes: F4, F5

AVDL transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -42,000
Change %: -100%
Price
Shares after: 0
Date: 12 Feb 2026
Ownership: By Trust
Underlying class: Ordinary Shares
Underlying amount: 42,000
Exercise price: $4.79
Footnotes: F4, F5

AVDL transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -33,000
Change %: -100%
Price
Shares after: 0
Date: 12 Feb 2026
Ownership: By Trust
Underlying class: Ordinary Shares
Underlying amount: 33,000
Exercise price: $14.10
Footnotes: F4, F5

AVDL transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -11,000
Change %: -100%
Price
Shares after: 0
Date: 12 Feb 2026
Ownership: By Trust
Underlying class: Ordinary Shares
Underlying amount: 11,000
Exercise price: $16.32
Footnotes: F4, F5

AVDL transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -25,000
Change %: -100%
Price
Shares after: 0
Date: 12 Feb 2026
Ownership: By Trust
Underlying class: Ordinary Shares
Underlying amount: 25,000
Exercise price: $10.93
Footnotes: F4, F5

AVDL transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -11,000
Change %: -100%
Price
Shares after: 0
Date: 12 Feb 2026
Ownership: By Trust
Underlying class: Ordinary Shares
Underlying amount: 11,000
Exercise price: $10.83
Footnotes: F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Linda Palczuk is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 5 footnotes

Footnote F1

Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by Amendment No. 1 to the Transaction Agreement dated November 18, 2025, (together the "Transaction Agreement") by and between Issuer and Alkermes plc ("Parent"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Parent acquired Issuer.

Footnote F2

Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $21.00 in cash (the "Cash Consideration") and a non-transferable contingent value right entitling the holders to a potential additional cash payment of $1.50 per share, contingent upon achievement of certain milestones (each a "CVR").

Footnote F3

Includes Ordinary Shares previously subject to vesting restrictions or forfeiture back to Issuer (each, a "Restricted Stock Award"). Pursuant to the Transaction Agreement, at the Effective Time, each Restricted Stock Award that was outstanding immediately prior to the Effective Time vested in full and was treated in the manner described in footnote 1.

Footnote F4

Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting).

Footnote F5

The Options are held by a revocable trust of which the Reporting Person is trustee.